Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 11 | 2018 | 334 | 3.850 |
Why?
|
| Tomography, X-Ray Computed | 22 | 2019 | 2324 | 3.650 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2018 | 689 | 2.600 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2016 | 163 | 2.160 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 5 | 2018 | 92 | 2.150 |
Why?
|
| Contrast Media | 12 | 2018 | 595 | 1.960 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 5 | 2019 | 373 | 1.900 |
Why?
|
| Liver | 7 | 2021 | 1118 | 1.810 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 6 | 2015 | 239 | 1.530 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2019 | 2223 | 1.340 |
Why?
|
| Cysts | 2 | 2021 | 70 | 1.330 |
Why?
|
| Sensitivity and Specificity | 15 | 2019 | 1753 | 1.230 |
Why?
|
| Liver Diseases | 3 | 2021 | 193 | 1.150 |
Why?
|
| Pancreatic Neoplasms | 3 | 2021 | 332 | 1.120 |
Why?
|
| Radiography, Abdominal | 4 | 2016 | 57 | 1.090 |
Why?
|
| Gadolinium DTPA | 3 | 2011 | 48 | 1.080 |
Why?
|
| Algorithms | 5 | 2018 | 1196 | 0.970 |
Why?
|
| Reproducibility of Results | 13 | 2019 | 2077 | 0.910 |
Why?
|
| Radiation Dosage | 5 | 2016 | 419 | 0.780 |
Why?
|
| Image Enhancement | 3 | 2015 | 143 | 0.780 |
Why?
|
| Biliary Tract | 2 | 2017 | 17 | 0.730 |
Why?
|
| Liver Cirrhosis | 2 | 2015 | 301 | 0.710 |
Why?
|
| Kidney Diseases, Cystic | 2 | 2019 | 31 | 0.670 |
Why?
|
| Retrospective Studies | 16 | 2019 | 7277 | 0.660 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 110 | 0.640 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 206 | 0.620 |
Why?
|
| Pancreas | 3 | 2015 | 225 | 0.620 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 63 | 0.610 |
Why?
|
| Cystadenoma | 1 | 2017 | 10 | 0.610 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2017 | 17 | 0.600 |
Why?
|
| Biliary Tract Diseases | 2 | 2017 | 50 | 0.590 |
Why?
|
| Male | 29 | 2019 | 37321 | 0.590 |
Why?
|
| Middle Aged | 24 | 2019 | 21147 | 0.580 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 778 | 0.580 |
Why?
|
| Humans | 40 | 2021 | 68618 | 0.570 |
Why?
|
| Aged | 20 | 2019 | 14862 | 0.560 |
Why?
|
| Portal Vein | 1 | 2016 | 46 | 0.560 |
Why?
|
| Signal-To-Noise Ratio | 4 | 2018 | 93 | 0.540 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2016 | 16 | 0.540 |
Why?
|
| Female | 26 | 2019 | 38074 | 0.510 |
Why?
|
| Liver Transplantation | 3 | 2019 | 400 | 0.500 |
Why?
|
| Pelvis | 2 | 2013 | 38 | 0.490 |
Why?
|
| Hemangioma | 1 | 2015 | 51 | 0.490 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 475 | 0.480 |
Why?
|
| Prospective Studies | 7 | 2018 | 3705 | 0.470 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2014 | 7 | 0.470 |
Why?
|
| Adult | 20 | 2019 | 21403 | 0.460 |
Why?
|
| Attitude of Health Personnel | 2 | 2015 | 442 | 0.460 |
Why?
|
| Catheterization, Peripheral | 1 | 2014 | 38 | 0.450 |
Why?
|
| Iron | 1 | 2015 | 197 | 0.440 |
Why?
|
| Pelvic Neoplasms | 1 | 2013 | 13 | 0.440 |
Why?
|
| Indium Radioisotopes | 1 | 2013 | 19 | 0.440 |
Why?
|
| Professional Competence | 1 | 2013 | 100 | 0.430 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2013 | 237 | 0.430 |
Why?
|
| Pancreatitis | 1 | 2015 | 279 | 0.420 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2013 | 137 | 0.420 |
Why?
|
| Crohn Disease | 1 | 2012 | 38 | 0.420 |
Why?
|
| Intestines | 1 | 2012 | 114 | 0.400 |
Why?
|
| Radiographic Image Enhancement | 5 | 2015 | 208 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 511 | 0.360 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 1140 | 0.350 |
Why?
|
| Observer Variation | 3 | 2016 | 330 | 0.330 |
Why?
|
| Carcinoma | 1 | 2010 | 215 | 0.310 |
Why?
|
| Aortic Diseases | 1 | 2008 | 113 | 0.290 |
Why?
|
| Cerebral Angiography | 1 | 2007 | 151 | 0.280 |
Why?
|
| Carotid Artery Diseases | 1 | 2007 | 83 | 0.280 |
Why?
|
| Feasibility Studies | 4 | 2012 | 652 | 0.260 |
Why?
|
| Radiation Protection | 2 | 2014 | 71 | 0.220 |
Why?
|
| Aged, 80 and over | 7 | 2017 | 4848 | 0.200 |
Why?
|
| Iohexol | 2 | 2012 | 82 | 0.200 |
Why?
|
| Machine Learning | 1 | 2021 | 170 | 0.170 |
Why?
|
| Paraspinal Muscles | 1 | 2019 | 5 | 0.170 |
Why?
|
| End Stage Liver Disease | 1 | 2019 | 60 | 0.160 |
Why?
|
| Adipose Tissue | 1 | 2019 | 221 | 0.150 |
Why?
|
| Cloud Computing | 1 | 2017 | 4 | 0.150 |
Why?
|
| Relative Value Scales | 1 | 2017 | 8 | 0.150 |
Why?
|
| Surgical Wound | 1 | 2017 | 8 | 0.150 |
Why?
|
| Endometriosis | 1 | 2017 | 56 | 0.150 |
Why?
|
| Logistic Models | 2 | 2011 | 1420 | 0.150 |
Why?
|
| Cicatrix | 1 | 2017 | 60 | 0.150 |
Why?
|
| Radiologists | 1 | 2017 | 35 | 0.150 |
Why?
|
| Administration, Oral | 1 | 2018 | 411 | 0.150 |
Why?
|
| Efficiency, Organizational | 1 | 2017 | 61 | 0.150 |
Why?
|
| Cesarean Section | 1 | 2017 | 101 | 0.150 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 189 | 0.150 |
Why?
|
| Workload | 1 | 2017 | 103 | 0.140 |
Why?
|
| Ethiodized Oil | 1 | 2016 | 4 | 0.140 |
Why?
|
| Cohort Studies | 1 | 2021 | 2358 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2019 | 7029 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2019 | 1342 | 0.130 |
Why?
|
| Metaphor | 1 | 2015 | 5 | 0.130 |
Why?
|
| Attitude to Death | 1 | 2015 | 52 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 3259 | 0.120 |
Why?
|
| Hamartoma | 1 | 2015 | 24 | 0.120 |
Why?
|
| User-Computer Interface | 1 | 2016 | 230 | 0.120 |
Why?
|
| Pancreatic Ducts | 1 | 2015 | 76 | 0.120 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2014 | 8 | 0.120 |
Why?
|
| Carcinoma, Ductal | 1 | 2014 | 14 | 0.120 |
Why?
|
| Appendiceal Neoplasms | 1 | 2014 | 9 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 18 | 0.120 |
Why?
|
| Mucocele | 1 | 2014 | 20 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 1 | 2014 | 23 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 111 | 0.110 |
Why?
|
| Arm | 1 | 2014 | 59 | 0.110 |
Why?
|
| Intestinal Diseases | 1 | 2013 | 25 | 0.110 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 41 | 0.110 |
Why?
|
| Veins | 1 | 2014 | 68 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2014 | 86 | 0.110 |
Why?
|
| Prostatectomy | 1 | 2014 | 87 | 0.110 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 215 | 0.110 |
Why?
|
| Time Factors | 2 | 2012 | 4655 | 0.110 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 53 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2014 | 99 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 201 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 138 | 0.110 |
Why?
|
| Violence | 1 | 2015 | 275 | 0.110 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2012 | 32 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 138 | 0.110 |
Why?
|
| Risk | 1 | 2014 | 563 | 0.100 |
Why?
|
| Prostate | 1 | 2013 | 116 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 274 | 0.100 |
Why?
|
| Incidence | 2 | 2014 | 1603 | 0.100 |
Why?
|
| Internet | 1 | 2015 | 390 | 0.100 |
Why?
|
| Biopsy | 1 | 2014 | 540 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2013 | 258 | 0.100 |
Why?
|
| Echo-Planar Imaging | 1 | 2011 | 17 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 306 | 0.090 |
Why?
|
| Reference Values | 1 | 2011 | 579 | 0.090 |
Why?
|
| Artifacts | 1 | 2011 | 125 | 0.090 |
Why?
|
| ROC Curve | 1 | 2011 | 392 | 0.090 |
Why?
|
| Coronavirus | 1 | 2010 | 16 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2010 | 93 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2014 | 413 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 2010 | 91 | 0.080 |
Why?
|
| Pheochromocytoma | 1 | 2009 | 22 | 0.080 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2009 | 26 | 0.080 |
Why?
|
| Adolescent | 5 | 2019 | 8912 | 0.080 |
Why?
|
| Ulcer | 1 | 2008 | 27 | 0.080 |
Why?
|
| Hematoma | 1 | 2008 | 47 | 0.080 |
Why?
|
| Aortic Aneurysm | 1 | 2008 | 77 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 711 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2009 | 346 | 0.070 |
Why?
|
| Coronavirus Infections | 1 | 2010 | 143 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1070 | 0.070 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 163 | 0.060 |
Why?
|
| Neoplasms | 1 | 2015 | 1667 | 0.060 |
Why?
|
| Young Adult | 3 | 2019 | 5717 | 0.040 |
Why?
|
| Infant | 3 | 2019 | 2891 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2019 | 3187 | 0.040 |
Why?
|
| Graft Survival | 1 | 2019 | 465 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1054 | 0.030 |
Why?
|
| Abdomen | 1 | 2016 | 80 | 0.030 |
Why?
|
| Iopamidol | 1 | 2015 | 37 | 0.030 |
Why?
|
| Child | 3 | 2019 | 6405 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 2014 | 47 | 0.030 |
Why?
|
| Omentum | 1 | 2014 | 18 | 0.030 |
Why?
|
| Peritoneum | 1 | 2014 | 27 | 0.030 |
Why?
|
| Appendectomy | 1 | 2014 | 47 | 0.030 |
Why?
|
| Colectomy | 1 | 2014 | 64 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2015 | 369 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 800 | 0.020 |
Why?
|
| Virology | 1 | 2010 | 11 | 0.020 |
Why?
|
| United Kingdom | 1 | 2010 | 152 | 0.020 |
Why?
|
| Seasons | 1 | 2010 | 129 | 0.020 |
Why?
|
| Adrenocortical Adenoma | 1 | 2009 | 2 | 0.020 |
Why?
|
| Catecholamines | 1 | 2009 | 73 | 0.020 |
Why?
|
| Protons | 1 | 2009 | 57 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 710 | 0.020 |
Why?
|
| Respiration | 1 | 2009 | 91 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 1426 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2010 | 2455 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2007 | 622 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 5731 | 0.010 |
Why?
|
| Poliovirus | 1 | 1972 | 4 | 0.010 |
Why?
|
| Immunity | 1 | 1972 | 67 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1972 | 110 | 0.010 |
Why?
|
| Serotyping | 1 | 1972 | 16 | 0.000 |
Why?
|
| Poliomyelitis | 1 | 1972 | 4 | 0.000 |
Why?
|
| Neutralization Tests | 1 | 1972 | 19 | 0.000 |
Why?
|
| Immunization Schedule | 1 | 1972 | 25 | 0.000 |
Why?
|
| Australia | 1 | 1972 | 235 | 0.000 |
Why?
|
| Vaccination | 1 | 1972 | 189 | 0.000 |
Why?
|